Literature DB >> 2942219

Effect of human atrial natriuretic peptide on blood pressure after sodium depletion in essential hypertension.

W M Janssen, P E de Jong, G K van der Hem, D de Zeeuw.   

Abstract

Human atrial natriuretic peptide was infused over four hours in three patients with essential hypertension. When the patients had a sodium intake of 200 mmol (mEq) daily an infusion of 0.5 micrograms atrial natriuretic peptide/min caused no significant change in blood pressure, whereas an infusion of 1.0 micrograms/min caused a gradual decrease in blood pressure and an increase in heart rate. After two to three hours of infusion with the higher dose two patients showed a sudden decrease in heart rate, with symptomatic hypotension. When the same patients had an intake of 50 mmol sodium daily their blood pressure was more sensitive to infusion of atrial natriuretic peptide; one patient again developed symptomatic hypotension, this time during an infusion of 0.5 micrograms/min. During all infusions distinct natriuresis occurred irrespective of whether blood pressure was affected. Prolonged, relatively low dose infusions of atrial natriuretic peptide can cause unwanted symptomatic hypotension. The effect on blood pressure is enhanced after sodium depletion, and blood pressure should be monitored carefully during longer infusions of atrial natriuretic peptide in patients with essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2942219      PMCID: PMC1341044          DOI: 10.1136/bmj.293.6543.351

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  4 in total

1.  Renal, haemodynamic, and hormonal effects of human alpha atrial natriuretic peptide in healthy volunteers.

Authors:  A M Richards; M G Nicholls; H Ikram; M W Webster; T G Yandle; E A Espiner
Journal:  Lancet       Date:  1985-03-09       Impact factor: 79.321

2.  Cardiac secretion of atrial natriuretic peptide.

Authors:  E A Espiner; I G Crozier; M G Nicholls; R Cuneo; T G Yondle; H Ikram
Journal:  Lancet       Date:  1985-08-17       Impact factor: 79.321

3.  Plasma atrial natriuretic peptide in cardiac disease and during infusion in healthy volunteers.

Authors:  I Tikkanen; F Fyhrquist; K Metsärinne; R Leidenius
Journal:  Lancet       Date:  1985-07-13       Impact factor: 79.321

4.  Cardiovascular effects of atrial extracts in anesthetized rats.

Authors:  U Ackermann; T G Irizawa; S Milojevic; H Sonnenberg
Journal:  Can J Physiol Pharmacol       Date:  1984-07       Impact factor: 2.273

  4 in total
  4 in total

1.  Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction.

Authors:  Melissa A Lyle; Seethalakshmi R Iyer; Margaret M Redfield; Yogesh N V Reddy; G Michael Felker; Thomas P Cappola; Adrian F Hernandez; Christopher G Scott; John C Burnett; Naveen L Pereira
Journal:  JACC Heart Fail       Date:  2019-08-07       Impact factor: 12.035

2.  Atrial natriuretic peptide decreases hepatic and cardiac blood content, but increases intestinal blood content in supine humans.

Authors:  J Peters; D Neuser; W Schaden; J O Arndt
Journal:  Basic Res Cardiol       Date:  1992 May-Jun       Impact factor: 17.165

Review 3.  Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update.

Authors:  Raymond Vanholder; Anneleen Pletinck; Eva Schepers; Griet Glorieux
Journal:  Toxins (Basel)       Date:  2018-01-08       Impact factor: 4.546

4.  Soluble neprilysin and long-term clinical outcomes in patients with coronary artery disease undergoing percutaneous coronary intervention: a retrospective cohort study.

Authors:  Ik Jun Choi; Sungmin Lim; Youngdeok Hwang; Dongjae Lee; Won Jik Lee; Kwan Yong Lee; Mi-Jeong Kim; Doo Soo Jeon
Journal:  BMC Cardiovasc Disord       Date:  2020-08-06       Impact factor: 2.298

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.